Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I, Open-label, Dose-escalating, Clinical and Pharmacokinetic Study of PM14 Administered Intravenously to Patients With Advanced Solid Tumors

Next Previous
X
Search
Trial Profile

Phase I, Open-label, Dose-escalating, Clinical and Pharmacokinetic Study of PM14 Administered Intravenously to Patients With Advanced Solid Tumors

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 17 Jun 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ecubectedin (Primary)
  • Indications Adrenocortical carcinoma; Advanced breast cancer; Carcinoma; Colorectal cancer; Ewing's sarcoma; Fallopian tube cancer; Gastric cancer; Intestinal cancer; Leiomyosarcoma; Liposarcoma; Malignant melanoma; Ovarian cancer; Pancreatic cancer; Peritoneal cancer; Prostate cancer; Solid tumours; Synovial sarcoma
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors PharmaMar

    • Most Recent Events

    • 13 Jun 2024 Planned End Date changed from 13 Feb 2023 to 13 Aug 2025.
    • 13 Jun 2024 Planned primary completion date changed from 13 Feb 2023 to 13 Aug 2025.
    • 25 Mar 2022 Status changed from active, no longer recruiting to recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top